nodes	percent_of_prediction	percent_of_DWPC	metapath
Nebivolol—CYP2D6—Lomustine—hematologic cancer	0.0838	0.189	CbGbCtD
Nebivolol—CYP2D6—Idarubicin—hematologic cancer	0.0747	0.168	CbGbCtD
Nebivolol—CYP2D6—Hydroxyurea—hematologic cancer	0.0635	0.143	CbGbCtD
Nebivolol—CYP2D6—Bortezomib—hematologic cancer	0.0552	0.124	CbGbCtD
Nebivolol—CYP2D6—Imatinib—hematologic cancer	0.0405	0.0912	CbGbCtD
Nebivolol—CYP2D6—Nilotinib—hematologic cancer	0.0368	0.0829	CbGbCtD
Nebivolol—CYP2D6—Vinorelbine—hematologic cancer	0.0365	0.0822	CbGbCtD
Nebivolol—CYP2D6—Vinblastine—hematologic cancer	0.0225	0.0506	CbGbCtD
Nebivolol—CYP2D6—Dexamethasone—hematologic cancer	0.0166	0.0375	CbGbCtD
Nebivolol—CYP2D6—Doxorubicin—hematologic cancer	0.0138	0.0311	CbGbCtD
Nebivolol—Asthenia—Irinotecan—hematologic cancer	0.000199	0.000414	CcSEcCtD
Nebivolol—Fatigue—Etoposide—hematologic cancer	0.000198	0.000414	CcSEcCtD
Nebivolol—Vomiting—Thalidomide—hematologic cancer	0.000197	0.000411	CcSEcCtD
Nebivolol—Dizziness—Carmustine—hematologic cancer	0.000197	0.000411	CcSEcCtD
Nebivolol—Rash—Thalidomide—hematologic cancer	0.000195	0.000408	CcSEcCtD
Nebivolol—Dermatitis—Thalidomide—hematologic cancer	0.000195	0.000407	CcSEcCtD
Nebivolol—Dizziness—Alitretinoin—hematologic cancer	0.000195	0.000407	CcSEcCtD
Nebivolol—Diarrhoea—Vincristine—hematologic cancer	0.000194	0.000406	CcSEcCtD
Nebivolol—Headache—Thalidomide—hematologic cancer	0.000194	0.000405	CcSEcCtD
Nebivolol—Asthenia—Gemcitabine—hematologic cancer	0.000193	0.000404	CcSEcCtD
Nebivolol—Dizziness—Ifosfamide—hematologic cancer	0.000193	0.000402	CcSEcCtD
Nebivolol—Pruritus—Gemcitabine—hematologic cancer	0.000191	0.000398	CcSEcCtD
Nebivolol—Nausea—Thiotepa—hematologic cancer	0.00019	0.000397	CcSEcCtD
Nebivolol—Diarrhoea—Mitoxantrone—hematologic cancer	0.000189	0.000395	CcSEcCtD
Nebivolol—Diarrhoea—Irinotecan—hematologic cancer	0.000189	0.000395	CcSEcCtD
Nebivolol—Vomiting—Carmustine—hematologic cancer	0.000189	0.000395	CcSEcCtD
Nebivolol—Insomnia—Triamcinolone—hematologic cancer	0.000189	0.000394	CcSEcCtD
Nebivolol—Gastrointestinal pain—Etoposide—hematologic cancer	0.000188	0.000393	CcSEcCtD
Nebivolol—Dizziness—Vincristine—hematologic cancer	0.000188	0.000392	CcSEcCtD
Nebivolol—Rash—Carmustine—hematologic cancer	0.000188	0.000392	CcSEcCtD
Nebivolol—Dermatitis—Carmustine—hematologic cancer	0.000188	0.000391	CcSEcCtD
Nebivolol—Vomiting—Alitretinoin—hematologic cancer	0.000188	0.000391	CcSEcCtD
Nebivolol—Paraesthesia—Triamcinolone—hematologic cancer	0.000187	0.000391	CcSEcCtD
Nebivolol—Headache—Carmustine—hematologic cancer	0.000186	0.000389	CcSEcCtD
Nebivolol—Shock—Betamethasone—hematologic cancer	0.000186	0.000389	CcSEcCtD
Nebivolol—Shock—Dexamethasone—hematologic cancer	0.000186	0.000389	CcSEcCtD
Nebivolol—Dyspnoea—Triamcinolone—hematologic cancer	0.000186	0.000389	CcSEcCtD
Nebivolol—Rash—Alitretinoin—hematologic cancer	0.000186	0.000388	CcSEcCtD
Nebivolol—Nervous system disorder—Dexamethasone—hematologic cancer	0.000186	0.000388	CcSEcCtD
Nebivolol—Nervous system disorder—Betamethasone—hematologic cancer	0.000186	0.000388	CcSEcCtD
Nebivolol—Dermatitis—Alitretinoin—hematologic cancer	0.000186	0.000388	CcSEcCtD
Nebivolol—Thrombocytopenia—Betamethasone—hematologic cancer	0.000185	0.000387	CcSEcCtD
Nebivolol—Thrombocytopenia—Dexamethasone—hematologic cancer	0.000185	0.000387	CcSEcCtD
Nebivolol—Vomiting—Ifosfamide—hematologic cancer	0.000185	0.000387	CcSEcCtD
Nebivolol—Hypersensitivity—Cisplatin—hematologic cancer	0.000185	0.000386	CcSEcCtD
Nebivolol—Bradycardia—Epirubicin—hematologic cancer	0.000185	0.000386	CcSEcCtD
Nebivolol—Headache—Alitretinoin—hematologic cancer	0.000185	0.000386	CcSEcCtD
Nebivolol—Angioedema—Prednisone—hematologic cancer	0.000185	0.000386	CcSEcCtD
Nebivolol—Diarrhoea—Gemcitabine—hematologic cancer	0.000184	0.000385	CcSEcCtD
Nebivolol—Nausea—Thalidomide—hematologic cancer	0.000184	0.000384	CcSEcCtD
Nebivolol—Rash—Ifosfamide—hematologic cancer	0.000184	0.000384	CcSEcCtD
Nebivolol—Dermatitis—Ifosfamide—hematologic cancer	0.000184	0.000383	CcSEcCtD
Nebivolol—Dizziness—Irinotecan—hematologic cancer	0.000183	0.000382	CcSEcCtD
Nebivolol—Urticaria—Etoposide—hematologic cancer	0.000183	0.000382	CcSEcCtD
Nebivolol—Abdominal pain—Etoposide—hematologic cancer	0.000182	0.00038	CcSEcCtD
Nebivolol—Vertigo—Prednisone—hematologic cancer	0.000182	0.000379	CcSEcCtD
Nebivolol—Syncope—Prednisone—hematologic cancer	0.000181	0.000378	CcSEcCtD
Nebivolol—Vomiting—Vincristine—hematologic cancer	0.000181	0.000377	CcSEcCtD
Nebivolol—Urticaria—Prednisolone—hematologic cancer	0.00018	0.000376	CcSEcCtD
Nebivolol—Asthenia—Cisplatin—hematologic cancer	0.00018	0.000376	CcSEcCtD
Nebivolol—Cardiac disorder—Methotrexate—hematologic cancer	0.00018	0.000376	CcSEcCtD
Nebivolol—Fatigue—Triamcinolone—hematologic cancer	0.00018	0.000376	CcSEcCtD
Nebivolol—Rash—Vincristine—hematologic cancer	0.000179	0.000374	CcSEcCtD
Nebivolol—Dermatitis—Vincristine—hematologic cancer	0.000179	0.000374	CcSEcCtD
Nebivolol—Oedema peripheral—Epirubicin—hematologic cancer	0.000179	0.000373	CcSEcCtD
Nebivolol—Headache—Vincristine—hematologic cancer	0.000178	0.000372	CcSEcCtD
Nebivolol—Loss of consciousness—Prednisone—hematologic cancer	0.000178	0.000371	CcSEcCtD
Nebivolol—Nausea—Carmustine—hematologic cancer	0.000177	0.000369	CcSEcCtD
Nebivolol—Vomiting—Mitoxantrone—hematologic cancer	0.000176	0.000367	CcSEcCtD
Nebivolol—Vomiting—Irinotecan—hematologic cancer	0.000176	0.000367	CcSEcCtD
Nebivolol—Nausea—Alitretinoin—hematologic cancer	0.000175	0.000366	CcSEcCtD
Nebivolol—Rash—Mitoxantrone—hematologic cancer	0.000174	0.000364	CcSEcCtD
Nebivolol—Rash—Irinotecan—hematologic cancer	0.000174	0.000364	CcSEcCtD
Nebivolol—Dermatitis—Mitoxantrone—hematologic cancer	0.000174	0.000364	CcSEcCtD
Nebivolol—Dermatitis—Irinotecan—hematologic cancer	0.000174	0.000364	CcSEcCtD
Nebivolol—Headache—Irinotecan—hematologic cancer	0.000173	0.000362	CcSEcCtD
Nebivolol—Headache—Mitoxantrone—hematologic cancer	0.000173	0.000362	CcSEcCtD
Nebivolol—Nausea—Ifosfamide—hematologic cancer	0.000173	0.000361	CcSEcCtD
Nebivolol—Diarrhoea—Cisplatin—hematologic cancer	0.000172	0.000359	CcSEcCtD
Nebivolol—Vomiting—Gemcitabine—hematologic cancer	0.000171	0.000358	CcSEcCtD
Nebivolol—Insomnia—Betamethasone—hematologic cancer	0.000171	0.000358	CcSEcCtD
Nebivolol—Insomnia—Dexamethasone—hematologic cancer	0.000171	0.000358	CcSEcCtD
Nebivolol—Bradycardia—Doxorubicin—hematologic cancer	0.000171	0.000357	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	0.000171	0.000357	CcSEcCtD
Nebivolol—Paraesthesia—Betamethasone—hematologic cancer	0.00017	0.000355	CcSEcCtD
Nebivolol—Paraesthesia—Dexamethasone—hematologic cancer	0.00017	0.000355	CcSEcCtD
Nebivolol—Mental disorder—Methotrexate—hematologic cancer	0.00017	0.000355	CcSEcCtD
Nebivolol—Rash—Gemcitabine—hematologic cancer	0.00017	0.000355	CcSEcCtD
Nebivolol—Dermatitis—Gemcitabine—hematologic cancer	0.00017	0.000354	CcSEcCtD
Nebivolol—Hypersensitivity—Etoposide—hematologic cancer	0.00017	0.000354	CcSEcCtD
Nebivolol—Malnutrition—Methotrexate—hematologic cancer	0.000169	0.000353	CcSEcCtD
Nebivolol—Headache—Gemcitabine—hematologic cancer	0.000169	0.000352	CcSEcCtD
Nebivolol—Nausea—Vincristine—hematologic cancer	0.000169	0.000352	CcSEcCtD
Nebivolol—Cardiac disorder—Epirubicin—hematologic cancer	0.000169	0.000352	CcSEcCtD
Nebivolol—Hypersensitivity—Prednisolone—hematologic cancer	0.000167	0.000349	CcSEcCtD
Nebivolol—Urticaria—Triamcinolone—hematologic cancer	0.000166	0.000346	CcSEcCtD
Nebivolol—Oedema peripheral—Doxorubicin—hematologic cancer	0.000166	0.000346	CcSEcCtD
Nebivolol—Asthenia—Etoposide—hematologic cancer	0.000165	0.000345	CcSEcCtD
Nebivolol—Nausea—Mitoxantrone—hematologic cancer	0.000164	0.000343	CcSEcCtD
Nebivolol—Nausea—Irinotecan—hematologic cancer	0.000164	0.000343	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000164	0.000341	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000164	0.000341	CcSEcCtD
Nebivolol—Fatigue—Dexamethasone—hematologic cancer	0.000163	0.000341	CcSEcCtD
Nebivolol—Fatigue—Betamethasone—hematologic cancer	0.000163	0.000341	CcSEcCtD
Nebivolol—Pruritus—Etoposide—hematologic cancer	0.000163	0.00034	CcSEcCtD
Nebivolol—Shock—Prednisone—hematologic cancer	0.000162	0.000339	CcSEcCtD
Nebivolol—Nervous system disorder—Prednisone—hematologic cancer	0.000162	0.000338	CcSEcCtD
Nebivolol—Skin disorder—Prednisone—hematologic cancer	0.00016	0.000334	CcSEcCtD
Nebivolol—Nausea—Gemcitabine—hematologic cancer	0.00016	0.000334	CcSEcCtD
Nebivolol—Vomiting—Cisplatin—hematologic cancer	0.00016	0.000333	CcSEcCtD
Nebivolol—Mental disorder—Epirubicin—hematologic cancer	0.000159	0.000332	CcSEcCtD
Nebivolol—Rash—Cisplatin—hematologic cancer	0.000158	0.000331	CcSEcCtD
Nebivolol—Dermatitis—Cisplatin—hematologic cancer	0.000158	0.00033	CcSEcCtD
Nebivolol—Malnutrition—Epirubicin—hematologic cancer	0.000158	0.00033	CcSEcCtD
Nebivolol—Diarrhoea—Etoposide—hematologic cancer	0.000158	0.000329	CcSEcCtD
Nebivolol—Cardiac disorder—Doxorubicin—hematologic cancer	0.000156	0.000326	CcSEcCtD
Nebivolol—Gastrointestinal pain—Dexamethasone—hematologic cancer	0.000155	0.000323	CcSEcCtD
Nebivolol—Gastrointestinal pain—Betamethasone—hematologic cancer	0.000155	0.000323	CcSEcCtD
Nebivolol—Hypersensitivity—Triamcinolone—hematologic cancer	0.000154	0.000321	CcSEcCtD
Nebivolol—Dizziness—Etoposide—hematologic cancer	0.000152	0.000318	CcSEcCtD
Nebivolol—Vertigo—Methotrexate—hematologic cancer	0.000152	0.000317	CcSEcCtD
Nebivolol—Urticaria—Betamethasone—hematologic cancer	0.000151	0.000314	CcSEcCtD
Nebivolol—Urticaria—Dexamethasone—hematologic cancer	0.000151	0.000314	CcSEcCtD
Nebivolol—Dizziness—Prednisolone—hematologic cancer	0.00015	0.000313	CcSEcCtD
Nebivolol—Asthenia—Triamcinolone—hematologic cancer	0.00015	0.000313	CcSEcCtD
Nebivolol—Abdominal pain—Betamethasone—hematologic cancer	0.00015	0.000313	CcSEcCtD
Nebivolol—Abdominal pain—Dexamethasone—hematologic cancer	0.00015	0.000313	CcSEcCtD
Nebivolol—Nausea—Cisplatin—hematologic cancer	0.000149	0.000311	CcSEcCtD
Nebivolol—Insomnia—Prednisone—hematologic cancer	0.000149	0.000311	CcSEcCtD
Nebivolol—Paraesthesia—Prednisone—hematologic cancer	0.000148	0.000309	CcSEcCtD
Nebivolol—Pruritus—Triamcinolone—hematologic cancer	0.000148	0.000308	CcSEcCtD
Nebivolol—Mental disorder—Doxorubicin—hematologic cancer	0.000147	0.000307	CcSEcCtD
Nebivolol—Vomiting—Etoposide—hematologic cancer	0.000146	0.000305	CcSEcCtD
Nebivolol—Malnutrition—Doxorubicin—hematologic cancer	0.000146	0.000305	CcSEcCtD
Nebivolol—Rash—Etoposide—hematologic cancer	0.000145	0.000303	CcSEcCtD
Nebivolol—Dermatitis—Etoposide—hematologic cancer	0.000145	0.000303	CcSEcCtD
Nebivolol—Headache—Etoposide—hematologic cancer	0.000144	0.000301	CcSEcCtD
Nebivolol—Chest pain—Methotrexate—hematologic cancer	0.000144	0.0003	CcSEcCtD
Nebivolol—Rash—Prednisolone—hematologic cancer	0.000143	0.000299	CcSEcCtD
Nebivolol—Dermatitis—Prednisolone—hematologic cancer	0.000143	0.000298	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	0.000143	0.000298	CcSEcCtD
Nebivolol—Fatigue—Prednisone—hematologic cancer	0.000142	0.000297	CcSEcCtD
Nebivolol—Headache—Prednisolone—hematologic cancer	0.000142	0.000297	CcSEcCtD
Nebivolol—Vertigo—Epirubicin—hematologic cancer	0.000142	0.000296	CcSEcCtD
Nebivolol—Syncope—Epirubicin—hematologic cancer	0.000142	0.000296	CcSEcCtD
Nebivolol—Loss of consciousness—Epirubicin—hematologic cancer	0.000139	0.00029	CcSEcCtD
Nebivolol—Dizziness—Triamcinolone—hematologic cancer	0.000138	0.000288	CcSEcCtD
Nebivolol—Nausea—Etoposide—hematologic cancer	0.000137	0.000285	CcSEcCtD
Nebivolol—Asthenia—Betamethasone—hematologic cancer	0.000136	0.000284	CcSEcCtD
Nebivolol—Asthenia—Dexamethasone—hematologic cancer	0.000136	0.000284	CcSEcCtD
Nebivolol—Nervous system disorder—Methotrexate—hematologic cancer	0.000135	0.000282	CcSEcCtD
Nebivolol—Thrombocytopenia—Methotrexate—hematologic cancer	0.000135	0.000282	CcSEcCtD
Nebivolol—Gastrointestinal pain—Prednisone—hematologic cancer	0.000135	0.000282	CcSEcCtD
Nebivolol—Nausea—Prednisolone—hematologic cancer	0.000135	0.000281	CcSEcCtD
Nebivolol—Chest pain—Epirubicin—hematologic cancer	0.000135	0.000281	CcSEcCtD
Nebivolol—Pruritus—Dexamethasone—hematologic cancer	0.000134	0.00028	CcSEcCtD
Nebivolol—Pruritus—Betamethasone—hematologic cancer	0.000134	0.00028	CcSEcCtD
Nebivolol—Skin disorder—Methotrexate—hematologic cancer	0.000134	0.00028	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	0.000134	0.000279	CcSEcCtD
Nebivolol—Vomiting—Triamcinolone—hematologic cancer	0.000133	0.000277	CcSEcCtD
Nebivolol—Rash—Triamcinolone—hematologic cancer	0.000132	0.000275	CcSEcCtD
Nebivolol—Dermatitis—Triamcinolone—hematologic cancer	0.000132	0.000275	CcSEcCtD
Nebivolol—Vertigo—Doxorubicin—hematologic cancer	0.000131	0.000274	CcSEcCtD
Nebivolol—Syncope—Doxorubicin—hematologic cancer	0.000131	0.000274	CcSEcCtD
Nebivolol—Urticaria—Prednisone—hematologic cancer	0.000131	0.000274	CcSEcCtD
Nebivolol—Headache—Triamcinolone—hematologic cancer	0.000131	0.000273	CcSEcCtD
Nebivolol—Abdominal pain—Prednisone—hematologic cancer	0.00013	0.000272	CcSEcCtD
Nebivolol—Diarrhoea—Dexamethasone—hematologic cancer	0.00013	0.000271	CcSEcCtD
Nebivolol—Diarrhoea—Betamethasone—hematologic cancer	0.00013	0.000271	CcSEcCtD
Nebivolol—Loss of consciousness—Doxorubicin—hematologic cancer	0.000129	0.000268	CcSEcCtD
Nebivolol—Shock—Epirubicin—hematologic cancer	0.000127	0.000265	CcSEcCtD
Nebivolol—Nervous system disorder—Epirubicin—hematologic cancer	0.000127	0.000264	CcSEcCtD
Nebivolol—Thrombocytopenia—Epirubicin—hematologic cancer	0.000126	0.000264	CcSEcCtD
Nebivolol—Skin disorder—Epirubicin—hematologic cancer	0.000125	0.000262	CcSEcCtD
Nebivolol—Dizziness—Dexamethasone—hematologic cancer	0.000125	0.000261	CcSEcCtD
Nebivolol—Dizziness—Betamethasone—hematologic cancer	0.000125	0.000261	CcSEcCtD
Nebivolol—Insomnia—Methotrexate—hematologic cancer	0.000125	0.00026	CcSEcCtD
Nebivolol—Chest pain—Doxorubicin—hematologic cancer	0.000125	0.00026	CcSEcCtD
Nebivolol—Nausea—Triamcinolone—hematologic cancer	0.000124	0.000259	CcSEcCtD
Nebivolol—Paraesthesia—Methotrexate—hematologic cancer	0.000124	0.000258	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	0.000124	0.000258	CcSEcCtD
Nebivolol—Dyspnoea—Methotrexate—hematologic cancer	0.000123	0.000257	CcSEcCtD
Nebivolol—Somnolence—Methotrexate—hematologic cancer	0.000123	0.000256	CcSEcCtD
Nebivolol—Hypersensitivity—Prednisone—hematologic cancer	0.000122	0.000254	CcSEcCtD
Nebivolol—Vomiting—Dexamethasone—hematologic cancer	0.00012	0.000251	CcSEcCtD
Nebivolol—Vomiting—Betamethasone—hematologic cancer	0.00012	0.000251	CcSEcCtD
Nebivolol—Rash—Betamethasone—hematologic cancer	0.000119	0.000249	CcSEcCtD
Nebivolol—Rash—Dexamethasone—hematologic cancer	0.000119	0.000249	CcSEcCtD
Nebivolol—Dermatitis—Betamethasone—hematologic cancer	0.000119	0.000249	CcSEcCtD
Nebivolol—Dermatitis—Dexamethasone—hematologic cancer	0.000119	0.000249	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Methotrexate—hematologic cancer	0.000119	0.000248	CcSEcCtD
Nebivolol—Fatigue—Methotrexate—hematologic cancer	0.000119	0.000248	CcSEcCtD
Nebivolol—Headache—Dexamethasone—hematologic cancer	0.000119	0.000248	CcSEcCtD
Nebivolol—Headache—Betamethasone—hematologic cancer	0.000119	0.000248	CcSEcCtD
Nebivolol—Asthenia—Prednisone—hematologic cancer	0.000118	0.000247	CcSEcCtD
Nebivolol—Shock—Doxorubicin—hematologic cancer	0.000117	0.000245	CcSEcCtD
Nebivolol—Nervous system disorder—Doxorubicin—hematologic cancer	0.000117	0.000244	CcSEcCtD
Nebivolol—Thrombocytopenia—Doxorubicin—hematologic cancer	0.000117	0.000244	CcSEcCtD
Nebivolol—Pruritus—Prednisone—hematologic cancer	0.000117	0.000244	CcSEcCtD
Nebivolol—Insomnia—Epirubicin—hematologic cancer	0.000117	0.000244	CcSEcCtD
Nebivolol—Skin disorder—Doxorubicin—hematologic cancer	0.000116	0.000242	CcSEcCtD
Nebivolol—Paraesthesia—Epirubicin—hematologic cancer	0.000116	0.000242	CcSEcCtD
Nebivolol—Dyspnoea—Epirubicin—hematologic cancer	0.000115	0.00024	CcSEcCtD
Nebivolol—Somnolence—Epirubicin—hematologic cancer	0.000115	0.000239	CcSEcCtD
Nebivolol—Diarrhoea—Prednisone—hematologic cancer	0.000113	0.000236	CcSEcCtD
Nebivolol—Gastrointestinal pain—Methotrexate—hematologic cancer	0.000113	0.000235	CcSEcCtD
Nebivolol—Nausea—Dexamethasone—hematologic cancer	0.000113	0.000235	CcSEcCtD
Nebivolol—Nausea—Betamethasone—hematologic cancer	0.000113	0.000235	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Epirubicin—hematologic cancer	0.000111	0.000233	CcSEcCtD
Nebivolol—Fatigue—Epirubicin—hematologic cancer	0.000111	0.000232	CcSEcCtD
Nebivolol—Urticaria—Methotrexate—hematologic cancer	0.00011	0.000229	CcSEcCtD
Nebivolol—Dizziness—Prednisone—hematologic cancer	0.000109	0.000228	CcSEcCtD
Nebivolol—Abdominal pain—Methotrexate—hematologic cancer	0.000109	0.000227	CcSEcCtD
Nebivolol—Insomnia—Doxorubicin—hematologic cancer	0.000108	0.000225	CcSEcCtD
Nebivolol—Paraesthesia—Doxorubicin—hematologic cancer	0.000107	0.000224	CcSEcCtD
Nebivolol—Dyspnoea—Doxorubicin—hematologic cancer	0.000106	0.000222	CcSEcCtD
Nebivolol—Somnolence—Doxorubicin—hematologic cancer	0.000106	0.000222	CcSEcCtD
Nebivolol—Gastrointestinal pain—Epirubicin—hematologic cancer	0.000106	0.00022	CcSEcCtD
Nebivolol—Vomiting—Prednisone—hematologic cancer	0.000105	0.000219	CcSEcCtD
Nebivolol—Rash—Prednisone—hematologic cancer	0.000104	0.000217	CcSEcCtD
Nebivolol—Dermatitis—Prednisone—hematologic cancer	0.000104	0.000217	CcSEcCtD
Nebivolol—Headache—Prednisone—hematologic cancer	0.000103	0.000216	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Doxorubicin—hematologic cancer	0.000103	0.000215	CcSEcCtD
Nebivolol—Fatigue—Doxorubicin—hematologic cancer	0.000103	0.000215	CcSEcCtD
Nebivolol—Urticaria—Epirubicin—hematologic cancer	0.000103	0.000214	CcSEcCtD
Nebivolol—Abdominal pain—Epirubicin—hematologic cancer	0.000102	0.000213	CcSEcCtD
Nebivolol—Hypersensitivity—Methotrexate—hematologic cancer	0.000102	0.000212	CcSEcCtD
Nebivolol—Asthenia—Methotrexate—hematologic cancer	9.89e-05	0.000206	CcSEcCtD
Nebivolol—Nausea—Prednisone—hematologic cancer	9.8e-05	0.000205	CcSEcCtD
Nebivolol—Gastrointestinal pain—Doxorubicin—hematologic cancer	9.76e-05	0.000204	CcSEcCtD
Nebivolol—Pruritus—Methotrexate—hematologic cancer	9.76e-05	0.000204	CcSEcCtD
Nebivolol—Hypersensitivity—Epirubicin—hematologic cancer	9.51e-05	0.000198	CcSEcCtD
Nebivolol—Urticaria—Doxorubicin—hematologic cancer	9.48e-05	0.000198	CcSEcCtD
Nebivolol—Abdominal pain—Doxorubicin—hematologic cancer	9.44e-05	0.000197	CcSEcCtD
Nebivolol—Diarrhoea—Methotrexate—hematologic cancer	9.43e-05	0.000197	CcSEcCtD
Nebivolol—Asthenia—Epirubicin—hematologic cancer	9.26e-05	0.000193	CcSEcCtD
Nebivolol—Pruritus—Epirubicin—hematologic cancer	9.13e-05	0.000191	CcSEcCtD
Nebivolol—Dizziness—Methotrexate—hematologic cancer	9.12e-05	0.00019	CcSEcCtD
Nebivolol—Diarrhoea—Epirubicin—hematologic cancer	8.83e-05	0.000184	CcSEcCtD
Nebivolol—Hypersensitivity—Doxorubicin—hematologic cancer	8.8e-05	0.000184	CcSEcCtD
Nebivolol—Vomiting—Methotrexate—hematologic cancer	8.77e-05	0.000183	CcSEcCtD
Nebivolol—Rash—Methotrexate—hematologic cancer	8.69e-05	0.000181	CcSEcCtD
Nebivolol—Dermatitis—Methotrexate—hematologic cancer	8.69e-05	0.000181	CcSEcCtD
Nebivolol—Headache—Methotrexate—hematologic cancer	8.64e-05	0.00018	CcSEcCtD
Nebivolol—Asthenia—Doxorubicin—hematologic cancer	8.57e-05	0.000179	CcSEcCtD
Nebivolol—Dizziness—Epirubicin—hematologic cancer	8.53e-05	0.000178	CcSEcCtD
Nebivolol—Pruritus—Doxorubicin—hematologic cancer	8.45e-05	0.000176	CcSEcCtD
Nebivolol—Vomiting—Epirubicin—hematologic cancer	8.2e-05	0.000171	CcSEcCtD
Nebivolol—Nausea—Methotrexate—hematologic cancer	8.19e-05	0.000171	CcSEcCtD
Nebivolol—Diarrhoea—Doxorubicin—hematologic cancer	8.17e-05	0.00017	CcSEcCtD
Nebivolol—Rash—Epirubicin—hematologic cancer	8.14e-05	0.00017	CcSEcCtD
Nebivolol—Dermatitis—Epirubicin—hematologic cancer	8.13e-05	0.00017	CcSEcCtD
Nebivolol—Headache—Epirubicin—hematologic cancer	8.08e-05	0.000169	CcSEcCtD
Nebivolol—Dizziness—Doxorubicin—hematologic cancer	7.9e-05	0.000165	CcSEcCtD
Nebivolol—Nausea—Epirubicin—hematologic cancer	7.66e-05	0.00016	CcSEcCtD
Nebivolol—Vomiting—Doxorubicin—hematologic cancer	7.59e-05	0.000158	CcSEcCtD
Nebivolol—Rash—Doxorubicin—hematologic cancer	7.53e-05	0.000157	CcSEcCtD
Nebivolol—Dermatitis—Doxorubicin—hematologic cancer	7.52e-05	0.000157	CcSEcCtD
Nebivolol—Headache—Doxorubicin—hematologic cancer	7.48e-05	0.000156	CcSEcCtD
Nebivolol—Nausea—Doxorubicin—hematologic cancer	7.09e-05	0.000148	CcSEcCtD
Nebivolol—ADRB1—Signaling Pathways—CD86—hematologic cancer	1.76e-05	0.000229	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—STAT5A—hematologic cancer	1.76e-05	0.000228	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—PIK3CB—hematologic cancer	1.75e-05	0.000228	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—JAK2—hematologic cancer	1.75e-05	0.000228	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CDKN2B—hematologic cancer	1.74e-05	0.000226	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—HES1—hematologic cancer	1.74e-05	0.000226	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—NCOR1—hematologic cancer	1.73e-05	0.000224	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—PIK3R1—hematologic cancer	1.72e-05	0.000224	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CD86—hematologic cancer	1.72e-05	0.000224	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—NCOA3—hematologic cancer	1.72e-05	0.000223	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ADCY7—hematologic cancer	1.72e-05	0.000223	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—JAK2—hematologic cancer	1.71e-05	0.000223	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—FGF1—hematologic cancer	1.71e-05	0.000222	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CSF2—hematologic cancer	1.71e-05	0.000222	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—NUP214—hematologic cancer	1.71e-05	0.000222	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—HES1—hematologic cancer	1.7e-05	0.000221	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—NCOR1—hematologic cancer	1.69e-05	0.00022	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CD86—hematologic cancer	1.69e-05	0.000219	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—FOXO1—hematologic cancer	1.68e-05	0.000219	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—IL2—hematologic cancer	1.68e-05	0.000219	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PDGFRB—hematologic cancer	1.68e-05	0.000218	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—JAK2—hematologic cancer	1.68e-05	0.000218	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CSF2—hematologic cancer	1.67e-05	0.000217	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—FGF1—hematologic cancer	1.67e-05	0.000217	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—MTR—hematologic cancer	1.67e-05	0.000217	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ABCG2—hematologic cancer	1.67e-05	0.000217	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—PIK3CB—hematologic cancer	1.66e-05	0.000216	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—HES1—hematologic cancer	1.66e-05	0.000216	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PDGFRA—hematologic cancer	1.65e-05	0.000215	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—NCOR1—hematologic cancer	1.65e-05	0.000215	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—JAK1—hematologic cancer	1.65e-05	0.000214	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PRKCG—hematologic cancer	1.65e-05	0.000214	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—FOXO1—hematologic cancer	1.65e-05	0.000214	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—IL2—hematologic cancer	1.65e-05	0.000214	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PDGFRB—hematologic cancer	1.64e-05	0.000214	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ENO2—hematologic cancer	1.64e-05	0.000213	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CSF2—hematologic cancer	1.63e-05	0.000212	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—FGF1—hematologic cancer	1.63e-05	0.000212	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—PIK3CB—hematologic cancer	1.63e-05	0.000211	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PDGFRA—hematologic cancer	1.62e-05	0.00021	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PRKCG—hematologic cancer	1.61e-05	0.00021	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—JAK1—hematologic cancer	1.61e-05	0.00021	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—FOXO1—hematologic cancer	1.61e-05	0.000209	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—IL2—hematologic cancer	1.61e-05	0.000209	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PDGFRB—hematologic cancer	1.61e-05	0.000209	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—PIK3CB—hematologic cancer	1.59e-05	0.000207	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—GSTT1—hematologic cancer	1.59e-05	0.000206	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PDGFRA—hematologic cancer	1.58e-05	0.000206	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PRKCG—hematologic cancer	1.58e-05	0.000205	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—JAK1—hematologic cancer	1.58e-05	0.000205	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—SDC1—hematologic cancer	1.55e-05	0.000202	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—IL2RA—hematologic cancer	1.54e-05	0.0002	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—IL2—hematologic cancer	1.53e-05	0.000199	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—TERT—hematologic cancer	1.52e-05	0.000198	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—IL2RA—hematologic cancer	1.51e-05	0.000196	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—IL2—hematologic cancer	1.5e-05	0.000194	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—TERT—hematologic cancer	1.49e-05	0.000193	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PDGFB—hematologic cancer	1.49e-05	0.000193	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—IL2RA—hematologic cancer	1.47e-05	0.000191	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—IL2—hematologic cancer	1.46e-05	0.00019	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—TERT—hematologic cancer	1.46e-05	0.000189	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PDGFB—hematologic cancer	1.45e-05	0.000189	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—TSC2—hematologic cancer	1.45e-05	0.000189	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PDGFB—hematologic cancer	1.42e-05	0.000185	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—TSC2—hematologic cancer	1.42e-05	0.000185	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—FGFR3—hematologic cancer	1.4e-05	0.000182	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—TSC2—hematologic cancer	1.39e-05	0.00018	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MAPK14—hematologic cancer	1.38e-05	0.00018	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—FGFR3—hematologic cancer	1.37e-05	0.000178	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—ESR1—hematologic cancer	1.36e-05	0.000176	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MAPK14—hematologic cancer	1.35e-05	0.000176	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—FN1—hematologic cancer	1.34e-05	0.000174	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—FGFR3—hematologic cancer	1.34e-05	0.000174	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—ESR1—hematologic cancer	1.33e-05	0.000172	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—BAD—hematologic cancer	1.32e-05	0.000172	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—NFKBIA—hematologic cancer	1.32e-05	0.000172	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MAPK14—hematologic cancer	1.32e-05	0.000172	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—NQO1—hematologic cancer	1.32e-05	0.000172	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CD44—hematologic cancer	1.32e-05	0.000172	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—NOTCH1—hematologic cancer	1.31e-05	0.00017	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—FN1—hematologic cancer	1.31e-05	0.00017	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—ESR1—hematologic cancer	1.3e-05	0.000169	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—BAD—hematologic cancer	1.3e-05	0.000168	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—NFKBIA—hematologic cancer	1.3e-05	0.000168	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CD80—hematologic cancer	1.29e-05	0.000167	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—NOTCH1—hematologic cancer	1.28e-05	0.000167	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—KIT—hematologic cancer	1.28e-05	0.000167	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PIK3CG—hematologic cancer	1.28e-05	0.000167	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—NRAS—hematologic cancer	1.28e-05	0.000167	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—FN1—hematologic cancer	1.28e-05	0.000167	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—BAD—hematologic cancer	1.27e-05	0.000165	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—NFKBIA—hematologic cancer	1.27e-05	0.000165	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PTPN11—hematologic cancer	1.26e-05	0.000164	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CD80—hematologic cancer	1.26e-05	0.000163	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	1.26e-05	0.000163	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—KIT—hematologic cancer	1.26e-05	0.000163	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	1.26e-05	0.000163	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—NOTCH1—hematologic cancer	1.26e-05	0.000163	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYCS—hematologic cancer	1.25e-05	0.000162	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	1.24e-05	0.000161	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	1.23e-05	0.00016	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CD80—hematologic cancer	1.23e-05	0.00016	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—MAPK3—hematologic cancer	1.23e-05	0.00016	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PIK3CG—hematologic cancer	1.23e-05	0.000159	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—KIT—hematologic cancer	1.23e-05	0.000159	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—NRAS—hematologic cancer	1.23e-05	0.000159	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CREB1—hematologic cancer	1.22e-05	0.000159	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—BRAF—hematologic cancer	1.21e-05	0.000157	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PTPN11—hematologic cancer	1.21e-05	0.000157	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	1.2e-05	0.000156	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CCL2—hematologic cancer	1.2e-05	0.000155	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CREB1—hematologic cancer	1.19e-05	0.000155	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—IL6R—hematologic cancer	1.19e-05	0.000155	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CREBBP—hematologic cancer	1.19e-05	0.000155	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—BRAF—hematologic cancer	1.18e-05	0.000153	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—MAPK3—hematologic cancer	1.18e-05	0.000153	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CCL2—hematologic cancer	1.17e-05	0.000152	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CREB1—hematologic cancer	1.17e-05	0.000152	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—IL6R—hematologic cancer	1.17e-05	0.000151	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	1.16e-05	0.000151	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—BRAF—hematologic cancer	1.15e-05	0.00015	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CCL2—hematologic cancer	1.14e-05	0.000148	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—IL6R—hematologic cancer	1.14e-05	0.000148	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CREBBP—hematologic cancer	1.14e-05	0.000148	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MAP2K1—hematologic cancer	1.14e-05	0.000147	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	1.13e-05	0.000146	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.12e-05	0.000145	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	1.11e-05	0.000144	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	1.1e-05	0.000143	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	1.1e-05	0.000143	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—GSTP1—hematologic cancer	1.1e-05	0.000143	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	1.09e-05	0.000142	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MAP2K1—hematologic cancer	1.09e-05	0.000141	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	1.08e-05	0.00014	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—FGF2—hematologic cancer	1.08e-05	0.00014	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PIK3CD—hematologic cancer	1.08e-05	0.00014	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—PIK3CA—hematologic cancer	1.07e-05	0.000139	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	1.07e-05	0.000138	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—FGF2—hematologic cancer	1.06e-05	0.000137	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—KRAS—hematologic cancer	1.06e-05	0.000137	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ABCB1—hematologic cancer	1.04e-05	0.000135	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	1.04e-05	0.000135	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—JAK2—hematologic cancer	1.04e-05	0.000134	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—FGF2—hematologic cancer	1.03e-05	0.000134	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PIK3R1—hematologic cancer	1.02e-05	0.000132	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	1.01e-05	0.000132	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—JAK2—hematologic cancer	1.01e-05	0.000132	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—GSTM1—hematologic cancer	1.01e-05	0.000131	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—NCOR1—hematologic cancer	1.01e-05	0.000131	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MDM2—hematologic cancer	1.01e-05	0.000131	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	9.93e-06	0.000129	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—JAK2—hematologic cancer	9.9e-06	0.000129	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MDM2—hematologic cancer	9.89e-06	0.000128	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MTOR—hematologic cancer	9.83e-06	0.000128	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	9.83e-06	0.000128	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—PIK3CA—hematologic cancer	9.7e-06	0.000126	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MDM2—hematologic cancer	9.67e-06	0.000126	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MTOR—hematologic cancer	9.62e-06	0.000125	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	9.62e-06	0.000125	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MTOR—hematologic cancer	9.4e-06	0.000122	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PIK3CB—hematologic cancer	9.4e-06	0.000122	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	9.39e-06	0.000122	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	9.23e-06	0.00012	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	9.18e-06	0.000119	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	9.13e-06	0.000119	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CASP3—hematologic cancer	9.04e-06	0.000117	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—IL2—hematologic cancer	9.03e-06	0.000117	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	9.03e-06	0.000117	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—IL6—hematologic cancer	8.98e-06	0.000117	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—HRAS—hematologic cancer	8.98e-06	0.000117	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—MTHFR—hematologic cancer	8.95e-06	0.000116	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	8.93e-06	0.000116	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CASP3—hematologic cancer	8.85e-06	0.000115	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—IL2—hematologic cancer	8.83e-06	0.000115	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CDKN1B—hematologic cancer	8.83e-06	0.000115	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CCND1—hematologic cancer	8.8e-06	0.000114	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—IL6—hematologic cancer	8.79e-06	0.000114	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—JUN—hematologic cancer	8.78e-06	0.000114	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—AKT1—hematologic cancer	8.73e-06	0.000113	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CASP3—hematologic cancer	8.65e-06	0.000112	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—IL2—hematologic cancer	8.64e-06	0.000112	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CCND1—hematologic cancer	8.61e-06	0.000112	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—IL6—hematologic cancer	8.59e-06	0.000112	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—JUN—hematologic cancer	8.59e-06	0.000112	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	8.52e-06	0.000111	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PTEN—hematologic cancer	8.5e-06	0.00011	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CCND1—hematologic cancer	8.42e-06	0.000109	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—JUN—hematologic cancer	8.4e-06	0.000109	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	8.33e-06	0.000108	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	8.31e-06	0.000108	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PTEN—hematologic cancer	8.31e-06	0.000108	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	8.29e-06	0.000108	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CDKN1A—hematologic cancer	8.15e-06	0.000106	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	8.13e-06	0.000106	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PTEN—hematologic cancer	8.13e-06	0.000106	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	8.11e-06	0.000105	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—EP300—hematologic cancer	8.1e-06	0.000105	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MAPK8—hematologic cancer	7.95e-06	0.000103	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—AKT1—hematologic cancer	7.93e-06	0.000103	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—EP300—hematologic cancer	7.93e-06	0.000103	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—SRC—hematologic cancer	7.88e-06	0.000102	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—EP300—hematologic cancer	7.75e-06	0.000101	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—SRC—hematologic cancer	7.71e-06	0.0001	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	7.67e-06	9.97e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—STAT3—hematologic cancer	7.6e-06	9.87e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—NRAS—hematologic cancer	7.58e-06	9.84e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—SRC—hematologic cancer	7.54e-06	9.79e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PIK3CG—hematologic cancer	7.52e-06	9.76e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	7.51e-06	9.75e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—STAT3—hematologic cancer	7.43e-06	9.65e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—NRAS—hematologic cancer	7.41e-06	9.63e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	7.34e-06	9.53e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—STAT3—hematologic cancer	7.27e-06	9.44e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	7.26e-06	9.43e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—NRAS—hematologic cancer	7.25e-06	9.42e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	7.1e-06	9.22e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MYC—hematologic cancer	7.06e-06	9.17e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	7.04e-06	9.15e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CREBBP—hematologic cancer	6.97e-06	9.05e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	6.94e-06	9.02e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MYC—hematologic cancer	6.91e-06	8.97e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	6.89e-06	8.95e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MYC—hematologic cancer	6.75e-06	8.77e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	6.74e-06	8.75e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PIK3CD—hematologic cancer	6.61e-06	8.58e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—KRAS—hematologic cancer	6.52e-06	8.47e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ALB—hematologic cancer	6.52e-06	8.47e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—KRAS—hematologic cancer	6.38e-06	8.29e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PIK3R1—hematologic cancer	6.24e-06	8.1e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—KRAS—hematologic cancer	6.24e-06	8.1e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	5.99e-06	7.78e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	5.86e-06	7.61e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—TP53—hematologic cancer	5.8e-06	7.53e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PIK3CB—hematologic cancer	5.76e-06	7.48e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	5.73e-06	7.45e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—TP53—hematologic cancer	5.67e-06	7.37e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—TP53—hematologic cancer	5.55e-06	7.2e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—HRAS—hematologic cancer	5.55e-06	7.2e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—HRAS—hematologic cancer	5.42e-06	7.04e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—IL6—hematologic cancer	5.31e-06	6.89e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—HRAS—hematologic cancer	5.3e-06	6.89e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—IL6—hematologic cancer	5.19e-06	6.74e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—IL6—hematologic cancer	5.08e-06	6.59e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PTEN—hematologic cancer	4.98e-06	6.46e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—AKT1—hematologic cancer	4.9e-06	6.36e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—AKT1—hematologic cancer	4.79e-06	6.22e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—EP300—hematologic cancer	4.75e-06	6.16e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—AKT1—hematologic cancer	4.68e-06	6.08e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PIK3CA—hematologic cancer	3.51e-06	4.56e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—AKT1—hematologic cancer	2.87e-06	3.73e-05	CbGpPWpGaD
